CSF2 and glioma: Therefore, the present trial was designed to evaluate the safety and immunological efficacy of low-dose reirradiation in combination with polyinosinic:polycytidylic acid (poly I:C) and granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients with recurrent WHO grade IV glioma.